Skip to content

Stroke rehabilitation robot control and precise intervention based on Neuroplasticity active induction

Stroke rehabilitation robot control and precise intervention based on Neuroplasticity active induction

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074561
Enrollment
Unknown
Registered
2023-08-09
Start date
2024-01-01
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stroke

Interventions

Intelligent Rehabilitation Group:Applying the precise intervention paradigm of active induction Neuroplasticity proposed in this project
traditional rehabilitation group:Bobath,CIMT, and FES

Sponsors

China research rehabilitation center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients or surrogates signed informed consent; first-onset ischemic stroke confirmed by imaging (based on MRI) ; course =3 months; age range 18-80 years; With moderate to severe upper extremity and hand dysfunction (upper extremity and hand Brunnstrom rating =4) ; upper extremity flexor muscle tension Ashworth rating =2; sitting balance rating =2; ability to perform 3 simple verbal commands; and ability to perform 3 tasks Corrected visual acuity =0.5 in at least one eye; able to follow all research procedures, participate in all treatments and assessments.

Exclusion criteria

Exclusion criteria: Contraindications to MRI (e.g. iron in the body, or artificial pacemaker) ; Major depression (HAMD depression rating scale > 17, geriatric depression rating scale > 10) , Severe cognitive impairment (EG: Montreal Cognitive Assessment <22) ; comorbidity with severe neurological or psychiatric disorders (including dementia, Parkinson's disease, etc.) in addition to stroke; comorbidity with severe medical conditions affecting patients throughout the trial (including, but not limited to, advanced chronic obstructive pulmonary disease, kidney failure and advanced heart failure) ; Other diseases (including but not limited to severe arthritis, Dupuytren contracture, amputation of =2 sites, etc.) that affect the functional recovery of the upper limbs of the stroke-affected side, have communication deficits and affect the participation of the study; Patients who received botulinum toxin injections to the extremities within the last 6 months; were unable or unwilling to undergo the study procedure or treatment, or patients do not meet the study procedure; life expectancy < 6 months; pregnancy; Taking part in another exploratory treatment study; speaking difficult dialects or other languages: because the Montreal Assessment (MOCA) scale is difficult to interpret for aphasia patients, exclusion criteria (MOCA score =22) could be determined by the lead investigator on a case-by-case basis.

Design outcomes

Primary

MeasureTime frame
MoCA;Motor function test;

Secondary

MeasureTime frame
NSE?GFAP;

Countries

China

Contacts

Public ContactLi Bingjie

China Rehabilitation Research Center

kaka0515@sohu.com+86 136 9363 9327

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026